Egypt, Germany, Hungary and Sweden make decisions on rosiglitazone
This article was originally published in SRA
Executive Summary
Regulators in Egypt, Germany, Hungary and Sweden have released statements on discontinuing the use of diabetes drugs containing rosiglitazone.